Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroblastoma

R P Castleberry1

  • 1Division of Pediatric Hematology/Oncology, University of Alabama at Birmingham, Children's Hospital 35233, USA.

European Journal of Cancer (Oxford, England : 1990)
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Neuroblastoma, a neural crest tumor, shows spontaneous regression but poor outcomes in disseminated childhood disease. Advances in tumor biology improve risk stratification for low-risk cases, but high-risk neuroblastoma requires further research and innovative therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005
Same author

Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study.

Neoplasia (New York, N.Y.)·2001
Same author

Residential pesticide exposure and neuroblastoma.

Epidemiology (Cambridge, Mass.)·2001
Same author

Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.

Journal of pediatric hematology/oncology·2000
Same author

Genetic analysis of childhood endodermal sinus tumors by comparative genomic hybridization.

Journal of pediatric hematology/oncology·2000
Same author

Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.

Blood·2000
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

Area of Science:

  • Pediatric Oncology
  • Cancer Biology
  • Translational Research

Background:

  • Neuroblastoma originates from neural crest cells and affects sympathetic ganglia and adrenal medulla.
  • It presents a paradox: high rates of spontaneous regression alongside poor outcomes in disseminated childhood disease.
  • Current risk-stratification models effectively manage low-risk neuroblastoma but show limited impact on high-risk cases.

Purpose of the Study:

  • To summarize the evolving biology of neuroblastoma.
  • To correlate tumor biology with current risk-related therapy.
  • To discuss future management strategies for neuroblastoma.

Main Methods:

  • Review of translational studies linking tumor biology and clinical features.
  • Analysis of prognostic grouping based on age (infants vs. children).

Related Experiment Videos

  • Examination of challenges in obtaining adequate tissue samples for high-risk neuroblastoma.

    • Main Results:

    • Translational studies have improved understanding and prediction of neuroblastoma natural history.
    • Risk-related management strategies have clarified treatment for lower-risk tumors.
    • Survival rates for high-risk neuroblastoma have seen minimal improvement.

    Conclusions:

    • Further research into the biology of high-risk neuroblastoma is crucial for developing innovative therapies.
    • Age-based prognostic grouping (infants <1 year vs. children ≥1 year) is a key factor in risk assessment.
    • Improved tissue sampling is needed to advance understanding and treatment of aggressive neuroblastoma.